Clinical Trials Logo

Human Papillomavirus Infection clinical trials

View clinical trials related to Human Papillomavirus Infection.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06362421 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer

Start date: August 2024
Phase:
Study type: Observational

The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer. In this study, the methods required to detect human papillomavirus will be developed and tested in samples collected from patients with oropharyngeal squamous cell carcinoma and compared to samples collected from participants without cancer.

NCT ID: NCT06281119 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Start date: June 2024
Phase: Phase 3
Study type: Interventional

Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly infected. The main burden of HPV-related disease is due to cervical cancer. Since cervical screening only detects precancerous and cancerous changes after they have occurred, HPV vaccination is primary prevention. People with HIV infection, even when effectively treated with antiretroviral therapy (ARV),are at higher risk of acquiring infection with multiple HPV types and are also known to be predisposed to a higher risk of HPV infection and subsequent CIN lesions. Vaccination of this high-risk group with HPV vaccine is highly beneficial. SIIPL's qHPV vaccine CERVAVAC®, India's first indigenous qHPV vaccine has received marketing authorization in India. The current study is a Phase 3b study to evaluate the immunogenicity and safety of two- and three-dose schedules of SIIPL qHPV vaccine in women living with HIV (WLWH) aged 15-25years.

NCT ID: NCT06245486 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses

Start date: February 10, 2024
Phase: N/A
Study type: Interventional

There is growing scientific interest in probiotic supplementation as a possible therapy for clearing the human papillomavirus (HPV) infection and reducing the risk of developement of cervical cancer.

NCT ID: NCT06213051 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Comparison of Self-collection Using Dry Compared to Wet Swabs for HPV Detection

HPV
Start date: April 1, 2024
Phase:
Study type: Observational

This study will compare the performance of self-collected vaginal swabs, transported without liquid media (dry swabs) and self-collected vaginal swabs, transported in liquid media (wet swabs) for detection of hrHPV DNA to screen for CIN2+ lesions using LBC as the reference standard.

NCT ID: NCT05981807 Not yet recruiting - Clinical trials for Sexually Transmitted Diseases

HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population

PrevHPV-TG
Start date: October 2023
Phase:
Study type: Observational

The goal of this observational study is to estimate the prevalence of HPV infections anal and ENT level and according to HIV status in transgender (TG) population. The main question it aims to answer is: - What is the prevalence of HPV lesions in transgender population (TG); - What kind of high risk HPV (hrHPV) and low risk HPV (lrHPV) are detected at the genital, anal and ENT level

NCT ID: NCT05672966 Not yet recruiting - Clinical trials for Human Papillomavirus Infection

Phase I Clinical Trial of a Candidate HPV Vaccine

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.

NCT ID: NCT04142398 Not yet recruiting - HIV Infection Clinical Trials

Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

Start date: April 30, 2025
Phase:
Study type: Observational

This research trial studies the incidence of human papilloma virus (HPV) infection and HPV-associated disease in screening Indian men who have sex with human immunodeficiency virus (HIV)-positive men. Gathering health information over time from Indian men who have sex with men (MSM) may help doctors determine how many HIV -positive MSM develop new HPV infections and how many HIV-positive MSM have HPV related disease.

NCT ID: NCT03813576 Not yet recruiting - Cervical Cancer Clinical Trials

Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study

Start date: March 2019
Phase: N/A
Study type: Interventional

In Singapore, the current cervical cancer screening uptake among women in Singapore has remained at low 50% since its introduction in 2004. It has been widely reported that under-screened women have the highest risk of cervical cancer. Self-sampling HPV DNA screening may be a solution to the low uptake rates of local women, particularly among the under-screened population in Singapore. Self-sampling comprises women using a swab to obtain samples from their vagina. In this study, we are comparing the sensitivity of detecting HPV positive women using HPV DNA test with self-sampling using flocked swab with the current physician sampling method. We also aim to determine acceptability of self-sampling HPV DNA test using flocked swab in cervical cancer screening. Designed as a feasibility study, it will comprise a prospective study of 300 women attending clinics in National University Hospital (NUH) and National Cancer Institute Singapore (NCIS).